Tuesday, 23 April 2019

Dermatoscopes Market 2018 – Industry Scenario, Strategies, Growth Factors and Forecast 2025

The global dermatoscopes market size is expected to reach USD 1.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 13.6% during the forecast period. Dermatoscopy plays a vital role in screening for skin cancer, which has resulted in early detection and identification of pigmented lesions. Benign pigmented moles possess a certain risk of developing melanoma.

Skin cancer is a chronic disease affecting a large population of the world. Rising incidence of melanoma and nonmelanoma skin cancers is providing an upthrust to the market. Certain moles, such as giant congenital pigmented hairy moles, are at high risk of developing melanoma. This has boosted the need for effective diagnosis with dermatoscopes.
In April 2016, The Skin Cancer Foundation initiated a month-long education and fundraising campaign during the Skin Cancer Awareness month. Early detection has been proved to be very useful in its effective treatment. Hence, rising number of awareness campaigns is estimated to fuel the demand for dermatoscopes, which is anticipated to propel the market. Earlier, the usage of these technologically advanced devices was limited to detection of noninvasive melanoma. However, with technological advancements, their application has widened to advanced diagnosis of various skin disorders.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • Contact dermatoscopes dominated the market in 2017 owing to abundant availability of these products
  • Hybrid dermatoscopes are anticipated to exhibit lucrative CAGR over the forecast period owing to unique features of contact as well as noncontact dermatoscopes
  • In 2017, LED technology held the largest market share owing to benefits associated with its usage, which include exact light intensity, color, and, homogeneity rendering precise diagnosis
  • Handheld devices generated maximum revenue share in 2017 due to the fact that they are relatively compact and consist of rechargeable batteries that enable easy manoeuvring across the body
  • Amongst end use segments, dermatology clinics dominated the market in 2017 and is also expected to exhibit attractive growth over the forecast period
  • The availability of sophisticated and technologically advanced medical equipment at dermatology clinics provides patients quick and rapid diagnosis, which helps deliver better treatment
  • North America held largest market share in 2017 owing to increase in the prevalence of skin cancer and growth in the adoption of advanced diagnostic technologies in this region
  • Asia Pacific is anticipated to exhibit attractive growth over the forecast period due to the introduction of novel technologies in countries such as Japan and China
  • Some of the key market participants are 3Gen; Optilia; Firefly Global; HEINE Optotechnik GmbH & Co. KG; FotoFinder Systems, Inc.; Caliber Imaging & Diagnostics, Inc.; ILLUCO Corporation Ltd.; Bio-Therapeutic, Inc.; and Welch Allyn

Monday, 22 April 2019

Increasing number of esthetic procedures is driving the dermatology devices market 2018-2025

The global dermatology devices market size is expected to reach a value of USD 25.7 billion by 2025 at a 13.5% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Dermatology devices are expected to grow at a faster rate due to rising concerns among people regarding esthetics. This has led to growing awareness about various types of esthetic procedures used for treating hair- and skin-related disorders. Since women are larger consumers of skin and haircare treatments, they are considered as key revenue generators for the market.

Incidence of skin disorders is continuously rising among people owing to irregular lifestyle and food habits. Psoriasis, acne, eczema, and skin lesions are some of the most common skin ailments. Melanoma is a life-threatening skin cancer, which often results due to these disorders. Dermatology diagnostic devices help in early diagnosis of such deadly cancerous diseases.
Obesity has emerged as a major cause for concern among both men and women. With fat removal procedures gaining much demand, liposuction is considered as an effective treatment option. Rise in disposable income is a key factor aiding demand for such procedures, further driving market demand. In addition, there have been several technological advancements in laser treatments and devices, making the market highly lucrative.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • By product, treatment devices dominated the market in 2017 due to rise in awareness among people regarding esthetics, which has led to rise in adoption of both surgical and non-surgical cosmetic procedures
  • On the basis of treatment device type, laser devices held a lucrative market share in 2017owing to its wide application in a variety of disease and cosmetic treatments
  • Based on diagnostic device application, skin cancer diagnosis has emerged asakey revenue generator owing to high diseaseprevalence, particularlymelanoma
  • By treatment device application, skin rejuvenation is expected to gain lucrative growth over the forecast period due to a large aging population base opting for these procedures
  • On the basis of end use, hospitals held a significant share in 2017. This can be attributed to rise in adoption of advanced infrastructure and enhanced services in these settings
  • North America dominated the global market in 2017 owing to growing awareness regarding esthetic appeal, higher disposable income, and greater availability of advanced treatment and surgical procedures
  • Some of the key players in the market are Alma Lasers GmbH; Cynosure, Inc.; Solta Medical, Inc.; Cutera, Inc.; Syneron Medical Ltd.; Canfield Scientific, Inc.; 3Gen; Aesthetic Group; Ambicare Health; and Image Derm, Inc.

Controlled Release Drug Delivery Market 2018: Upcoming Demands & Growth Analysis to 2025

The global controlled release drug delivery market size is expected to reach USD 90.18 billion by 2025, according to a new report by Grand View Research, Inc., experiencing a CAGR of 14.0% during the forecast period. Soaring need for geriatric and pediatric controlled release delivery techniques and alternative therapies and rising awareness regarding benefits of these systems over conventional forms are providing a fillip to the market.

These technologies offer various benefits over traditional delivery forms. Reduced dosage and dosage frequency, less gastrointestinal side effects, enhanced patient compliance, uniform drug effect, improved drug efficacy and safety, and reduced fluctuation of plasma drug levels are some of the benefits offered by these technologies.
Dysphagia in geriatric population and unpleasant taste of pediatric dosages are playing a vital role in boosting the adoption of controlled release drug delivery systems. According to a report published by Orbis Biosciences, with reduction in frequency of dosages, compliance rates are witnessed to increase. Innovations in various drug delivery systems has been providing geriatric and pediatric population with easy solutions, which are further propelling the market. Controlled release of drugs allows reduction in overdose in elderly population as they can be altered according to required dosage over a specific period of time.
North America is estimated to be at the forefront of the market throughout the forecast period due to technologically advanced infrastructure, increasing R&D activities, and presence of major players and pharmaceutical companies in the region. Emerging countries such as India, China, and Brazil are also anticipated to register promising growth during the same period owing to improving healthcare infrastructure and medical technologies to cater to specific patient care. On similar lines, Asia Pacific is projected to post the highest CAGR during the forecast period.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • On the basis of application, oral controlled release systems held the largest share in the market in 2017 owing to increasing usage and ease of convenience offered for administration of medication
  • Targeted drug delivery is poised to be the fastest growth technology segment during the forecast period owing to its various benefits
  • Osmotic delivery, based on activation modulation drug delivery systems, is likely to witness the highest CAGR due to its ability to not be affected by various factors, such as pH, food consumption, and gastrointestinal motility
  • Asia Pacific is expected to post the highest CAGR during the forecast period owing to rising investments by dominant players in the region and developments in the of pharmaceutical industry in emerging countries, such as India and China
  • Some of the prominent companies operating in the market are Orbis Biosciences, Inc.; Merck and Co., Inc.; Alkermes plc; Johnson and Johnson; Coating Place, Inc.; Corium International, Inc.; Depomed, Inc.; Pfizer, Inc; Aradigm Corporation; and Capsugel.

Tuesday, 16 April 2019

Precision Medicine Market 2018: Global Size, Share, Emerging Trends, Demand and Revenue up to 2025

The global precision medicine (diagnostics/therapeutics) market size is expected to reach USD 85.5 billion by 2025 at a 9.9% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Trends such as introduction of cost-effective genomic and molecular biology testing methods, increasing prevalence of cancer and rare diseases, and rising use of big data in precision medicine are some of the key factors boosting market growth.

The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing. These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses. Today, the prevalence of diseases in areas such as oncology, immunology, and neurology has rapidly increased across the globe.
Researchers, healthcare professionals, and big pharma and biotech companies are working together to recognize new focused treatments options for the wellbeing of patients. Currently, there are many therapies and drugs under clinical trials for treatment of different types of cancers. Moreover, researchers have also shown an inclination toward development of precision medicines and diagnostics in non-oncologic disease areas.
Apart from therapeutics, the diagnostics field has also witnessed rapid growth in the past few years. The use of next generation sequencing (NGS), biomarkers, companion diagnostics, and esoteric tests can possibly change and affect prescription patterns of pharmaceutical medicines. Personalized medicines have very high chances of becoming a massive success in the next 20 years and have the capacity to treat and cure a few obstinate illnesses, which was not possible before.
Involvement of government and regulatory bodies has played a very important role in the growth of this field. In 2015, the then U.S. government announced the launch of the Precision Medicine Initiative. The following year, China launched the China Precision Medicine Initiative, which is a 15-year project that aims to build the country as a leader in development of precision therapies.
At present, more than 40% of the medications in biotech and pharmaceutical companies’ improvement pipeline incorporate biomarkers. The overview likewise recommended that some biopharmaceutical organizations have collaborated and joint their ventures in the past five years and are expected to continue doing so in the coming years. The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • Technologies such as gene sequencing, biomarkers, big data analytics, and companion diagnostics are anticipated to drive this market in the coming years
  • By end use, clinical labs held the dominant share in the market in 2017. The home care testing segment, on the other hand, has been witnessing rapid growth due to its speed, efficiency, and convenience
  • On the basis of indication area, therapeutic precision medicines for oncology held the largest market share in 2017. However, there has been a change in focus of researchers toward the development of precision medicines for non-oncologic diseases. This has resulted in greater focus on immunological, genetic, and rare diseases
  • The North America market currently holds the largest share and is expected to grow further during the forecast period. The market is primarily driven by supportive policies and initiatives by the government and strong presence of market players. Asia Pacific is expected to emerge as the fastest growing region in this market
  • GE Healthcare; Abbott Laboratories; Precision Biologics; Foundation Medicine; Illumina, Inc.; and IBM Watson are some of the prominent players in the precision medicine diagnostics market and precision medicine therapeutics market

Antinuclear Antibody Test Market 2018 Share, Production and Consumption Analysis, Growth Factors, Brands Statistics and Overview by Top Manufacturers 2025

The global antinuclear antibody test market size is expected to reach USD 2.36 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.

Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.
Extension of ANA from a test for SLE to a test for any autoimmune diseases has boosted the usage of antinuclear antibody testing. An increase in ANA demand may also be due to the factors such as expanded role of primary care physicians in healthcare delivery systems. In addition, rising R&D activities and government initiatives regarding early diagnosis of autoimmune disorders have triggered the demand for ANA tests.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • Reagents and assay kits was the largest segment in 2017. It is likely to witness fastest growth over the forecast period due to wide usage and rise in a number of reagent rental agreements
  • Immunofluorescence assay led the market in terms of market share in 2017 owing to superior sensitivity compared to other available techniques
  • ELISA is expected to be the fastest growing segment over the forecast period. Increasing adoption of these tests is attributed to easy automation and handling without high level of operator skill
  • Rheumatoid arthritis segment is projected to hold largest market share, mainly due to high prevalence of the disease
  • North America was the largest region in terms of revenue in 2017, followed by Europe. Both are the most well-established regions in terms of the adoption of ANA testing and make up most of the existing market
  • Asia Pacific is likely to be the fastest growing region over the forecast period due to unmet clinical needs and need for better diagnosis. Rising government initiatives and clinical research activities for advanced diagnostics are expected to further fuel growth
  • Key players operating in the antinuclear antibody test market are Thermo Fisher Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC; Zeus Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.

Monday, 15 April 2019

Mammalian Polyclonal IgG Antibody Market 2018 : Industry Growth & Opportunities up to 2025

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.21 billion by 2025 expanding at a CAGR of 5.1%, according to a new report by Grand View Research, Inc. Advantages over other forms of antibodies, increasing global R&D investments, and rising adoption of novel diagnostic procedures are factors driving the market. Global rise in chronic and infectious diseases also play a key role in propelling the market growth.

Polyclonal antibodies are the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these does not require skilled professionals and large batches can be produced as per client requirements. A polyclonal antibody can recognize multiple antigens on one epitope and therefore can be utilized in the study of various diseases ranging from cancer to metabolic diseases. Denatured proteins are often detected with the use of polyclonal antibodies.
Thus, increasing use of these products in the treatment of several chronic diseases is also anticipated to fuel growth in the near future. Rising investments by major pharma companies, such as Novartis and Roche, for the development of therapeutic antibodies and novel diagnostic techniques and for QC purposes are also driving the market growth. For instance, R&D investments by top 10 biotech companies increased from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, accounting for a 13% increase.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • Large amount of polysera obtained from goats and predominant use of these animals as hosts has contributed to its large market share in 2017
  • Metabolic biomarkers are expected to hold the largest market share during the forecast period due to growing prevalence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer
  • ELISA tests provide accurate diagnosis of disease, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial and viral infections, than other antibody-based assays contributing to its high market share
  • Availability of technologically advanced equipment and presence of major market players has attributed to the North American region garnering large market share
  • Asia Pacific is anticipated to gain significant market share in near future due to rising R&D investment and presence of target population
  • Few key companies in the global mammalian polyclonal IgG antibody market include Abcam PLC; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific; Merck KgaA; Cell Signaling Technologies, Inc.; and Hoffmann-La Roche Ltd.

Global Retinal Implant Market 2018 Share, Manufacturing Cost Structure, and Forecast to 2026

The global retinal implant market size is expected to reach USD 74.7 million by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.6% over the forecast period. Increasing prevalence of target diseases, and rising geriatric population are the key driving factors for the market. Rising capability of restoring vision is anticipated to bode well for demand over the forecast period.

Laser therapy and Photodynamic Therapy (PTD) and some of the conventional treatments available for Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). Drugs such as Lucentis, Macugen, Eylea, and Vitamin A are a part of therapeutic treatment. Such treatments aid in reducing disease progression and thereby, delaying blindness. However, none of these treatments can completely cure the disease and restore vision. As a result, treatment procedures that restore vision are highly in demand.
Currently approved devices are capable of restoring vision with the help of electrodes, camera chips, lenses, software, and other tools. Moreover, implantable miniature telescope, Argus II is easy to use and enables patients to carry out their daily activities with ease. Furthermore, these devices can be used for a prolonged period of time, eliminating the need for another surgery. Therefore, the capability of advanced implantable devices to restore vision is expected to propel the market growth in near future.
Increasing geriatric population and rising disposable income in developing economies such as Japan, China, and India are also expected to boost the retinal implant market over the forecast period. Moreover, increasing healthcare expenditure by governments and private sectors and initiatives by major market players to operate in untapped regions are also anticipated to propel the growth in the forthcoming years.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • In terms of revenue, implantable miniature telescope segment is projected to expand at the highest CAGR over the forecast period. Increasing prevalence of AMD among geriatric population and usage of implantable devices to treat vision problems might drive the segment’s growth over the forecast period
  • In 2026, Asia-Pacific market is expected to witness the fastest CAGR over the forecast period owing to increasing geriatric population and disposable income
  • VisionCare, Inc.; Retina Implant AG; and Second Sight Medical Products, Inc. are expected to dominate the retinal implant market over the forecast period.